ClinicalTrials.gg
CompletedNCT03602560Updated Aug 2, 2022Results posted

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

A Phase 3 interventional study of seladelpar 5-10 mg and seladelpar 10 mg in Primary Biliary Cholangitis, sponsored by Gilead Sciences. Completed at 156 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-02.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
3rd of 10
265 · median 126
Started
2018
the only one that year
Phase 3
5 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 5 in phase 3, and was the 5th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)

The participants might enter the ongoing open-label safety study (NCT03301506) following this double-blind study.

Read the detailed description

Primary:

  • To evaluate the safety and effect on cholestasis of two seladelpar regimens (5 mg/day titrated to 10 mg/day and 10 mg/day) over 52 weeks of treatment compared to placebo

Key Secondary:

  • To evaluate the effect of seladelpar on normalization of alkaline phosphatase (AP) levels
  • To evaluate the effect of seladelpar on pruritus
03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • PBC
  • Primary Biliary Cholangitis (PBC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated) and any authorizations required by local law
  2. 18 to 75 years old (inclusive)
  3. Male or female with a diagnosis of PBC, by at least two of the following criteria:

    • History of AP above for at least six months
    • Positive anti-mitochondrial antibody (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay [ELISA]) or positive PBC-specific antinuclear antibodies
    • Documented liver result consistent with PBC
  4. On a stable and recommended dose of UDCA for the past twelve months OR intolerant to UDCA (last dose of UDCA > 3 months prior to Screening)
  5. AP ≥ 1.67 × ULN
  6. Females of must use at least one barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to seladelpar (MBX-8025)
  2. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer)
  3. above 3 ×
  4. ALT above 3 × ULN
  5. Total above 2.0 × ULN
  6. Advanced PBC as defined by the Rotterdam criteria (albumin below LLN AND total bilirubin above 1 × ULN)
  7. Creatine kinase (CK) above 1.0 × ULN
  8. below 60 mL/min/1.73 m2 (calculated by MDRD formula)
  9. (INR) above 1.0 × ULN
  10. count below 100 × 103/µL
  11. Presence of hepatic decompensation, including:

    • History of liver transplantation, current placement on liver transplantation list, or current MELD score ≥ 15
    • Complications of portal hypertension, including known esophageal varices, history of variceal bleeds or related interventions (e.g., transjugular intrahepatic portosystemic shunt placement), relevant ascites, hepatic encephalopathy
    • Cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis
  12. Other chronic liver diseases:

    • Current features of auto-immune hepatitis as determined by the investigator based on immunoserology, liver biochemistry and histology
    • Primary sclerosing cholangitis determined by presence of diagnostic cholangiographic findings
    • History or clinical evidence of alcoholic liver disease
    • History or clinical evidence of alpha-1-antitrypsin deficiency
    • confirmed nonalcoholic steatohepatitis
    • History or evidence of Gilbert' Syndrome with elevated total bilirubin
    • History or evidence of hemochromatosis
    • defined as presence of hepatitis B surface antigen (HBsAg)
    • defined as presence of HCV RNA
  13. Known history of
  14. Evidence of significant alcohol consumption
  15. Evidence of drug abuse
  16. Subjects with inadequate response to obeticholic acid (OCA) or intolerance to OCA: OCA must be discontinued 30 days prior to Screening
  17. Use of colchicine, methotrexate, azathioprine, or long-term systemic (> 2 weeks) within two months prior to Screening
  18. Use of fibrates within 30 days prior to Screening
  19. Use of simvastatin within 7 days prior to Screening
  20. Use of an experimental or unapproved treatment for PBC within 30 days prior to Screening
  21. Use of experimental or unapproved within 30 days prior to Screening
  22. Treatment with any other therapy or device within 30 days or within five half-lives, whatever is longer, prior to Screening
  23. For females, pregnancy or breast-feeding
  24. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the investigator
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Seladelpar 5-10 mg

    Drug: seladelpar 5-10 mg

  • Experimental
    Seladelpar 10 mg

    Drug: seladelpar 10 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drugseladelpar 5-10 mg

    Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study

  • Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study

  • DrugPlacebo

    One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3

    Percentage of Participants with Response to Composite Endpoint of ALP \<1.67 × Upper Limit of Normal \[ULN\], ≥15% reduction in ALP, and total bilirubin ≤ ULN) at Month 3. The mITT analysis set included all randomized subjects who received at least one study drug dose. The primary endpoint was analyzed using Cochran-Mantel-Haenszel (CMH) test adjusted for both randomization stratification variables (ALP level: \<350 U/L and 2:350 U/L; pruritus NRS: \<4 and 2:4). The CMH tests were performed for the comparison of 10 mg versus placebo and 5 mg/10 mg versus placebo separately.

    Time frame: Month 3

Secondary outcomes

  1. Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Month 3

    The response was defined by normalized ALP levels (ALP ≤1.0 × ULN) at endpoint. The mITT analysis set included all randomized subjects who received at least one study drug dose.

    Time frame: Month 3

  2. Change From Baseline in Pruritus NRS for Subjects With Baseline NRS ≥4 at Month 3

    Pruritus Numerical Rating Scale (NRS) used to rate the intensity of the worst itching you experienced in the past 24 hours from no itching to worst possible itching by selecting a number from 0 to 10 on Itch Scale. Zero means no itching and 10 means worst imaginable itching. The analysis will be limited to those subjects in the mITT analysis set with a baseline NRS ≥ 4.

    Time frame: Month 3

07

Results

Posted May 31, 2022

Participant flow

Participant flow — Overall Study
MilestoneSeladelpar 5-10 mgSeladelpar 10 mgPlacebo
Started898987
Completed111
Not completed888886

Outcome measures

PrimaryPercentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3

Percentage of Participants with Response to Composite Endpoint of ALP \<1.67 × Upper Limit of Normal \[ULN\], ≥15% reduction in ALP, and total bilirubin ≤ ULN) at Month 3. The mITT analysis set included all randomized subjects who received at least one study drug dose. The primary endpoint was analyzed using Cochran-Mantel-Haenszel (CMH) test adjusted for both randomization stratification variables (ALP level: \<350 U/L and 2:350 U/L; pruritus NRS: \<4 and 2:4). The CMH tests were performed for the comparison of 10 mg versus placebo and 5 mg/10 mg versus placebo separately.

Time frame:
Month 3
Reported as:
Count of participants · Participants
Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3
ParticipantsSeladelpar 5-10 mgSeladelpar 10 mgPlacebo
Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 332437
Statistical analysis
  • Seladelpar 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
  • Seladelpar 5-10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryPercentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Month 3

The response was defined by normalized ALP levels (ALP ≤1.0 × ULN) at endpoint. The mITT analysis set included all randomized subjects who received at least one study drug dose.

Time frame:
Month 3
Reported as:
Count of participants · Participants
Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Month 3
ParticipantsSeladelpar 5-10 mgSeladelpar 10 mgPlacebo
Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Month 33150
Statistical analysis
  • Seladelpar 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
  • Seladelpar 5-10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0839
SecondaryChange From Baseline in Pruritus NRS for Subjects With Baseline NRS ≥4 at Month 3

Pruritus Numerical Rating Scale (NRS) used to rate the intensity of the worst itching you experienced in the past 24 hours from no itching to worst possible itching by selecting a number from 0 to 10 on Itch Scale. Zero means no itching and 10 means worst imaginable itching. The analysis will be limited to those subjects in the mITT analysis set with a baseline NRS ≥ 4.

Time frame:
Month 3
Reported as:
Mean · score on a scale
Change From Baseline in Pruritus NRS for Subjects With Baseline NRS ≥4 at Month 3
score on a scaleSeladelpar 5-10 mgSeladelpar 10 mgPlacebo
Change From Baseline in Pruritus NRS for Subjects With Baseline NRS ≥4 at Month 3-1.95 ± 2.226-3.01 ± 1.952-1.44 ± 1.831
Statistical analysis
  • Seladelpar 10 mg vs Placebo · ANCOVA · p = 0.0164 · Risk difference (rd): -1.59 · 95% CI -2.87 to -0.3
  • Seladelpar 5-10 mg vs Placebo · ANCOVA · p = 0.4781 · Risk difference (rd): -0.46 · 95% CI -1.77 to 0.84

Adverse events

Collected over An AE will be recorded any time after the time of signed ICF and captured until this double-blinded study's last study visit, up to 1 year.. Non-serious events are listed at a 3.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Seladelpar 5/10 mg0/89 (0%)3/89 (3.4%)55/89 (61.8%)
Seladelpar 10 mg0/89 (0%)1/89 (1.1%)58/89 (65.2%)
Placebo0/87 (0%)3/87 (3.4%)62/87 (71.3%)
Most frequent serious events
Most frequent serious events
EventSeladelpar 5/10 mgSeladelpar 10 mgPlacebo
Rectal polypGastrointestinal disorders0/890/891/87
Pyelonephritis acuteInfections and infestations0/890/891/87
Partial seizuresNervous system disorders0/890/891/87
LeukocytosisBlood and lymphatic system disorders1/890/890/87
CellulitisInfections and infestations0/891/890/87
Adenoid cystic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/890/890/87
Cognitive disorderNervous system disorders1/890/890/87
Most frequent other events
Showing 10 of 25
Most frequent other events
EventSeladelpar 5/10 mgSeladelpar 10 mgPlacebo
PruritusSkin and subcutaneous tissue disorders3/8910/8911/87
FatigueGeneral disorders2/894/898/87
Abdominal pain upperGastrointestinal disorders8/896/893/87
NauseaGastrointestinal disorders5/897/894/87
HeadacheNervous system disorders5/897/891/87
Upper respiratory tract infectionInfections and infestations6/894/892/87
SinusitisInfections and infestations2/891/895/87
ArthralgiaMusculoskeletal and connective tissue disorders5/894/895/87
ConstipationGastrointestinal disorders5/893/892/87
Dry mouthGastrointestinal disorders5/891/890/87

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Seladelpar 5-10 mgSeladelpar 10 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years757373221
>=65 years14161444
Sex: Female, Male
Sex: Female, Male(Participants)Seladelpar 5-10 mgSeladelpar 10 mgPlaceboTotal
Female828385250
Male76215
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Seladelpar 5-10 mgSeladelpar 10 mgPlaceboTotal
American Indian or Alaska Native1001
Asian48517
Native Hawaiian or Other Pacific Islander0000
Black or African American1427
White837780240
More than one race0000
Unknown or Not Reported0000
08

Study locations

156 sites
  • Institute for Liver Health
    Chandler, Arizona 85224, United States
  • Mayo Clinic Arizona - PPDS
    Phoenix, Arizona 85054, United States
  • The Institute for Liver Health-Tucson
    Tucson, Arizona 85711, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford University School of Medicine
    Redwood City, California 94063, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Univeristy of Colorado Denver and Hospital
    Aurora, Colorado 80045, United States
  • Yale School of Medicine Digestive Diseases, Internal Medicine
    New Haven, Connecticut 06510, United States
  • Excel Medical Clinical Trials, LLC
    Boca Raton, Florida 33434, United States
  • Florida Reserach Institute
    Lakewood Ranch, Florida 34211, United States
  • Schiff Center for Liver Diseases University of Miami
    Miami, Florida 33136, United States
  • Tampa General Medical Group
    Tampa, Florida 33606, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indianapolis Gastroenterology Research Foundation
    Indianapolis, Indiana 46237, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Minnesota Gastroenterlogy, P.A.
    Maplewood, Minnesota 55117, United States
  • University of Minnesota Medical Center, Fairview
    Minneapolis, Minnesota 55455, United States
  • Southern Therapy and Advance Research (STAR) LLC
    Jackson, Mississippi 39216, United States
  • Digestive Health Specialists PA
    Tupelo, Mississippi 38801, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Concorde Medical Group
    New York, New York 10016, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Center for Liver Disease and Transplantation
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Asheville Gastroenterology Associates, a Division of Digestive Health Partners, P.A.
    Asheville, North Carolina 28801, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • UH Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Northeast Clinical Research Center, LLC
    Bethlehem, Pennsylvania 18017, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • GIA Clinical Trials, LLC
    Knoxville, Tennessee 37909, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Liver Institute at Methodist Dallas
    Dallas, Texas 75203, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Digestive Disease Consultants
    Fort Worth, Texas 76104, United States
  • American Research Corporation
    Houston, Texas 77030, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • Mary Immaculate Hospital
    Newport News, Virginia 23602, United States
  • Bon Secours Richmond Community Hospital
    Richmond, Virginia 23226, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Hospital Universitario Austral
    Pilar, Buenos Aires B1629AHJ, Argentina
  • Fundación Sanatorio Güemes
    Buenos Aires, Ciudad Autónoma De BuenosAires C1180AAX, Argentina
  • Hospital Provincial Del Centenario
    Rosario, Santa Fe S2000KDS, Argentina
  • DIM Clínica Privada
    Ramos Mejía, B1704ETD, Argentina
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Medizinische Universitat Wien
    Vienna, Wien A-1090, Austria
  • LKH-Universitätsklinikum Klinikum Graz
    Graz, 8036, Austria
  • Salzburger Landeskliniken
    Salzburg, 5020, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Wels, 4600, Austria
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • UZ Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • University of Calgary Medicine
    Calgary, Alberta T2N 4Z6, Canada
  • University of Manitoba
    Winnipeg, Manitoba R3E 3P4, Canada
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
  • Toronto Digestive Disease Associates Inc
    Vaughan, Ontario M3N 2V7, Canada
  • McGill University Health Centre (MUHC)
    Montréal, Quebec H4A 3J1, Canada
  • Pontificia Universidad Catolica de Chile
    Santiago, Región-MetropolitanadeSantiago 8330034, Chile
  • Centro Clinico Mediterraneo
    La Serena, 1720506, Chile
  • Centro de Investigaciones Clínicas Vina del Mar
    Viña Del Mar, 2540364, Chile
  • Hôpital Jean Verdier
    Bondy, 93140, France
  • CHU de GRENOBLE
    Grenoble, 38043, France
  • Hôpital Saint Antoine
    Paris, 75012, France
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • Gastroenterologische Gemeinschaftspraxis Herne
    Herne, Nordrhein-Westfalen 44623, Germany
  • Uniklinik Köln
    Köln, Nordrhein-Westfalen 50937, Germany
  • Gastroenterologisch Hepatologisches Zentrum Kiel
    Kiel, Schleswig-Holstein 24146, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • ifi-Institute for Interdisciplinary Medicine
    Hamburg, 20246, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • University General Hospital of Heraklion
    Heraklion, 71110, Greece
  • University General Hospital of Larissa
    Larissa, 41110, Greece
  • University General Hospital of Patras
    Patras, 26504, Greece
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, Csongrád 6720, Hungary
  • Budai Hepatológiai Centrum
    Budapest, 1111, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, 7400, Hungary
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Carmel Medical Center
    Haifa, 31048, Israel
  • Rambam Health Corporation
    Haifa, 31096, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • The Galilli Medical Center
    Nahariya, 22100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52662, Israel
  • Kaplan Medical Center
    Reẖovot, 76100, Israel

Showing the first 100 of 156 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2020, 16 months.

Results were first posted in May 2022, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2018
First posted
Jul 27, 2018
StartActual
Oct 1, 2018
Primary completionActual
Feb 16, 2020
CompletionActual
Feb 16, 2020
Results first posted
May 31, 2022
Last update
Aug 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03602560
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Oct 1, 2018
Primary completion
Feb 16, 2020
Completion
Feb 16, 2020
Results posted
May 31, 2022
Last update
Aug 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion